Volume 33, Issue 4 pp. 315-317

Case Report

Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 − 1G → A)

Dawn Simon MD,

Dawn Simon MD

Department of Pediatrics, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Search for more papers by this author

Michael Cimino RPh,

Michael Cimino RPh

Department of Pharmacy, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Search for more papers by this author

Drucy Borowitz MD,

Corresponding Author

Drucy Borowitz MD

[email protected]

Department of Pediatrics, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Department of Pediatrics, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, NY 14222.Search for more papers by this author

Dawn Simon MD,

Dawn Simon MD

Department of Pediatrics, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Search for more papers by this author

Michael Cimino RPh,

Michael Cimino RPh

Department of Pharmacy, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Search for more papers by this author

Drucy Borowitz MD,

Corresponding Author

Drucy Borowitz MD

[email protected]

Department of Pediatrics, Children's Hospital of Buffalo, State University of New York at Buffalo, Buffalo, New York

Department of Pediatrics, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, NY 14222.Search for more papers by this author

First published: 11 March 2002

https://doi.org/10.1002/ppul.10072

Citations: 1

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

A mother and daughter pair with CF who shared a splice mutation (1717 − 1G → A) had a normal volume of distribution of tobramycin. The literature on tobramycin pharmacokinetics, which was published before the genetic defect was identified, is discussed. The authors speculate on the role of CFTR in the distribution of aminoglycosides and recommend that CFTR mutations should be clarified in all future studies of tobramycin pharmacokinetics in patients with CF. Pediatr Pulmonol. 2002; 33:315-317. © 2002 Wiley-Liss, Inc.

REFERENCES

1 Aronoff SC, Beall RJ, Burns JL, Consensus Committee. Microbiology and infectious disease in cystic fibrosis. Consensus Conference. In: Clinical practice guidelines for CF, May 1994, volume V, section 1. Bethesda, MD: Cystic Fibrosis Foundation.
Google Scholar
2 Kearns GL, Hillman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 1982; 100: 312–318.
10.1016/S0022-3476(82)80663-X
CAS PubMed Web of Science® Google Scholar
3 Kelly HB, Menendez R, Fan L, Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr 1982; 100: 318–321.
10.1016/S0022-3476(82)80664-1
CAS PubMed Web of Science® Google Scholar
4 Touw DJ, Vinks AATMM, Jacobs F, Heijerman GM, Bakker W. Creatinine clearance as a predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther Drug Monit 1996; 18: 562–569.
10.1097/00007691-199610000-00007
CAS PubMed Web of Science® Google Scholar
5 Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984; 105: 117–124.
10.1016/S0022-3476(84)80375-3
CAS PubMed Web of Science® Google Scholar
6 Bosso JA. Cystic fibrosis. In: JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey, editors. Pharmacotherapy: a pathophysiologic approach. Stamford: Appleton & Lange; 1997. p 649–662.
Google Scholar
7 Azcue M, Fried M, Pencharz P. Use of bioelectric impedance analysis to measure total body water in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1993; 16: 440–445.
10.1002/j.1536-4801.1993.tb10893.x
CAS PubMed Web of Science® Google Scholar
8 Borowitz D, Conboy K. Are bioelectric impedance measurements valid in patients with cystic fibrosis? J Pediatr Gastroenterol Nutr 1994; 18: 453–456.
10.1002/j.1536-4801.1994.tb11213.x
CAS PubMed Web of Science® Google Scholar
9 Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238–243.
10.1002/ppul.1950010504
CAS PubMed Google Scholar
10 MacDonald N, Anas N, Peterson R, Schwartz R, Brooks J, Powell K. Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983; 103: 985–990.
10.1016/S0022-3476(83)80737-9
CAS PubMed Web of Science® Google Scholar
11 Beringer PM, Vinks AA, Jelliffe RW, Heijerman GH, Shapiro BJ. Evaluation of genotypic differences in the pharmacokinetics of tobramycin in an adult CF population. Pediatr Pulmonol [Suppl] 1999; 19: 261.
Google Scholar
12 Padoan R, Giunta A, Marzano MT, Seia M, Raia V, Ferrari M, Cremonesi L. First report of three cystic fibrosis patients homozygous for the 1717 − 1G → A mutation. J Med Genet 1996; 33: 1052–1054.
10.1136/jmg.33.12.1052-b
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume33, Issue4

April 2002

Pages 315-317

Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 − 1G → A)

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 − 1G → A)

Abstract

REFERENCES

Citing Literature

References

Related

Information